On June 1, 2023, the Company’s stockholders approved an amendment and restatement of the 2018 Omnibus Plan (the “2018 A&R Omnibus Plan”) which increased the number of shares available for issuance to 2,050,000 shares using stock options, stock appreciation rights, restricted stock, RSUs, performance units and PSAs, cash-based awards, and other stock-based awards to all key officers, key employees, and non-employee directors of the Company. As of December 31, 2024, the Company had approximately 1,016,040 shares available for grant under the A&R 2018 Omnibus Plan.

Stock-based compensation expense is included as part of direct costs and indirect and selling expenses on the consolidated statements of comprehensive income. The total stock-based compensation expense for the years ended December 31, 2024, 2023, and 2022, the unrecognized compensation expense at December 31, 2024, and the weighted-average period to recognize the remaining unrecognized shares are as follows:


	Stock-Based Compensation Expense
	Recognized as of December 31,						Unrecognized as of December 31,
	2024		2023		2022		2024		Weighted Average Period to Recognize (years)
Restricted Stock Units	$	10,654	$	9,413	$	9,300	$	13,910		1.5
Cash-Settled Restricted Stock Units		8,341		8,061		5,709		7,648		1.3
Non-Employee Director Awards		972		1,029		1,087		408		0.4
Performance Shares		5,096		4,416		2,784		5,177		1.4
Total	$	25,063	$	22,919	$	18,880	$	27,143

The stock-based compensation expense is deductible for income tax purposes. For the years ended December 31, 2024, 2023, and 2022, the Company recognized excess income tax benefits of $2.4 million, $1.1 million, and $1.1 million, respectively, related to stock-based compensation.

RSUs generally have a vesting term of three years. On vesting the employee is issued one share of stock for each RSU awarded. The fair value of shares vested was $10.3 million, $7.3 million, and $10.8 million for the years ended December 31, 2024, 2023, and 2022, respectively.

A summary of the Company’s RSUs is presented below.


	Number of Shares			Weighted- Average Grant Date Fair Value		Aggregate Intrinsic Value
Non-vested RSUs at January 1, 2022		303,836		$	79.17
Granted		148,361		$	93.70
Vested		(140,666	)	$	76.53
Cancelled		(26,705	)	$	77.16
Non-vested RSUs at December 31, 2022		284,826		$	88.23
Granted		89,388		$	110.80
Vested		(93,881	)	$	78.05
Cancelled		(21,815	)	$	94.01
Non-vested RSUs at December 31, 2023		258,518		$	99.25
Granted		86,428		$	153.22
Vested		(107,168	)	$	95.65
Cancelled		(26,807	)	$	109.79
Non-vested RSUs at December 31, 2024		210,971		$	121.86	$	25,150
RSUs expected to vest in the future		192,949		$	120.99	$	23,002

The aggregate intrinsic value in the preceding table is based on the Company’s closing stock price of $119.21 per share as of December 31, 2024.

CSRSUs generally have a vesting term of three years. The fair value of CSRSUs vested and settled in cash for the years ended December 31, 2024, 2023, and 2022 was $7.8 million, $7.9 million and $6.6 million, respectively. A summary of the Company’s CSRSUs is presented below.


	Number of Shares			Weighted- Average Grant Date Fair Value		Aggregate Intrinsic Value
Non-vested CSRSUs at January 1, 2022		166,260		$	72.79
Granted		115,024		$	97.88
Vested		(75,566	)	$	73.20
Cancelled		(17,299	)	$	80.02
Non-vested CSRSUs at December 31, 2022		188,419		$	87.28
Granted		70,742		$	110.65
Vested		(81,537	)	$	76.26
Cancelled		(19,040	)	$	91.94
Non-vested CSRSUs at December 31, 2023		158,584		$	102.82
Granted		38,653		$	153.15
Vested		(58,078	)	$	99.30
Cancelled		(9,424	)	$	114.93
Non-vested CSRSUs at December 31, 2024		129,735		$	118.51	$	15,466
CSRSUs expected to vest in the future		117,615		$	117.55	$	14,021

The aggregate intrinsic value in the preceding table is based on the Company’s closing stock price of $119.21 per share as of December 31, 2024.

The Company grants awards of registered shares to its non-employee directors on an annual basis under the A&R Omnibus Plan. A summary of the non-employee director awards is presented below:


	Number of Shares			Weighted- Average Grant Date Fair Value		Aggregate Intrinsic Value
Non-vested RSUs at January 1, 2022		5,586		$	90.73
Granted		11,399		$	95.35
Vested		(11,637	)	$	93.39
Cancelled		—		$	—
Non-vested RSUs at December 31, 2022		5,348		$	94.79
Granted		8,211		$	127.81
Vested		(9,457	)	$	109.14
Cancelled		—		$	—
Non-vested RSUs at December 31, 2023		4,102		$	127.81
Granted		6,618		$	135.91
Vested		(7,414	)	$	131.43
Cancelled		—		$	—
Non-vested RSUs at December 31, 2024		3,306		$	135.91	$	394
RSUs expected to vest in the future		3,306		$	135.91	$	394

The aggregate intrinsic value in the preceding table is based on the Company’s closing stock price of $119.21 per share as of December 31, 2024.

In 2015, the Board approved a performance-based share program (the “Program”) that provides for the issuance of PSAs to its senior management. Under the Program, the number of PSAs that the participant will receive depends on the Company’s achievement of two performance goals during two performance periods. The performance goals under the Program are based on (i) the Company’s compounded annual growth rate in EPS (adjusted to exclude certain items specified in the award’s agreement) during a two-year performance period (the “Initial Period”) and (ii) the Company’s cumulative total shareholder return relative to its peer group (“rTSR”) during a performance period from the first day of the performance period (typically January 1 of the year awarded) to the last day of the third year of the performance period (typically December 31). The PSAs will only be eligible to vest following the expiration of the three-year performance period. The actual shares vested will be subject to both continued employment by the Company (barring certain exceptions allowing for partial performance periods) and actual financial measures achieved. The final number of shares of common stock that will be issued to each participant at the end of the applicable performance period will be determined by multiplying the award by the product of two percentages: the first based on the Company’s EPS performance and the second based on the Company’s rTSR performance, subject to a minimum and maximum performance level. As of December 31, 2024, shares granted during 2022, 2023, and 2024 are within year three, two, and one of the performance periods, respectively, and therefore have not fully vested. A total of 46,630 shares granted in 2021 vested during 2024 after meeting the performance goals. As of December 31, 2024, a total of 59,863 shares granted in 2022 and 2023 are expected to vest in the future based on estimated financial measures achieved in the Initial Period and rTSR performance.

A summary of the Company’s PSAs is presented below.


	Number of Shares			Weighted- Average Grant Date Fair Value		Aggregate Intrinsic Value
Non-vested PSAs at January 1, 2022		133,079		$	76.54
Granted		38,412		$	93.15
Vested		(47,634	)	$	82.38
Cancelled		(3,170	)	$	80.64
Non-vested PSAs at December 31, 2022		120,687		$	79.42
Granted		36,956		$	115.67
Vested		(45,141	)	$	58.76
Cancelled		(6,934	)	$	61.49
Non-vested PSAs at December 31, 2023		105,568		$	102.12
Granted		41,365		$	143.97
Vested		(46,630	)	$	95.72
Cancelled		(4,198	)	$	114.91
Non-vested PSAs at December 31, 2024		96,105		$	122.68	$	11,457
PSAs expected to vest in the future		59,863		$	138.01	$	7,136

The aggregate intrinsic value in the preceding table is based on the Company’s closing stock price of $119.21 per share as of December 31, 2024.

The fair value of the awards is estimated on the grant date using a Monte Carlo simulation model due to the market condition for the rTSR component. The fair value assumptions using the Monte Carlo simulation model for awards granted in 2024, 2023, and 2022 were:


	2024			2023			2022
Dividend Yield		0.4	%		0.5	%		0.6	%
Historical Volatility		29.3	%		33.6	%		39.0	%
Risk-Free Rate of Returns		4.4	%		3.8	%		2.1	%